Alligator Bioscience rights issue

Alligator Bioscience

Subscription price: 0.10 SEK per unit
Brokerage fee: No brokerage fee
Issuance amount: Approximately 281 million SEK
Subscription period: January 29 -  february 12 2025
Trading in unit rights: January 29 -  february 7 2025
Trading in BTU:  Trading in BTU will take place on Nasdaq Stockholm from and including 29 January 2025 up to and including 4 March 2025
Marketplace: Nasdaq Stockholm
Company website: https://alligatorbioscience.se/en/

About Alligator Bioscience
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company’s lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.